Dividends per Share

Veru Inc. (VERU) paid N/A in dividends per share over the trailing twelve months.

Dividends Overview|Dividend Yield History|Dividends CAGR|Payout Ratio|FCF Payout Ratio

VERU Annual Dividends per Share (Dividend History)

This step chart displays the nominal dividend payouts over time by ex-dividend date, matching the distribution frequency (typically quarterly or semi-annually).

VERU Dividend Yield

Full Dividend Yield page

Dividend Yield

VERU Dividend Yield Chart

0.73%

Reported quarterly values; no daily interpolation.

+0.3pp over Max

Annual Dividend History List

Ex-Dividend Date	Nominal Dividend / Share	Distribution Change
Apr 28, 2014	$0.07	N/A
Jan 27, 2014	$0.07	N/A
Oct 28, 2013	$0.07	N/A
Jul 29, 2013	$0.07	N/A
Apr 29, 2013	$0.07	+16.67% Hike
Jan 28, 2013	$0.06	N/A
Oct 29, 2012	$0.06	N/A
Jul 30, 2012	$0.06	N/A
Apr 30, 2012	$0.06	+20.00% Hike
Jan 30, 2012	$0.05	N/A
Oct 31, 2011	$0.05	N/A
Jul 29, 2011	$0.05	N/A
Apr 29, 2011	$0.05	N/A
Jan 27, 2011	$0.05	N/A
Nov 1, 2010	$0.05	N/A
Aug 2, 2010	$0.05	N/A
Apr 21, 2010	$0.05	N/A
Jan 27, 2010	$0.05	N/A

About Veru Inc.

Veru Inc. operates as a biopharmaceutical firm primarily dedicated to advancing novel therapeutic agents for various types of cancer. Commercially, Veru markets the FC2 internal condom, designed to offer dual protection against both unplanned pregnancies and the transmission of sexually transmitted infections. This product is distributed globally to a diverse clientele, including governmental health departments, UN organizations, non-profit entities, and commercial distributors. Its robust development pipeline features a range of investigational therapies, notably within oncology: Enobosarm, an orally administered selective androgen receptor agonist, is progressing through Phase III clinical trials for treating metastatic breast cancer that is AR+, ER+, and HER2-negative. Sabizabulin is undergoing Phase IIb studies for the same type of metastatic breast cancer. Furthermore, a combination therapy of Enobosarm with abemaciclib is in Phase III for AR+ ER+ HER2- metastatic breast cancer. For metastatic triple-negative breast cancer, Veru is exploring a combination of Sabizabulin (an oral targeted cytoskeleton disruptor) and Enobosarm (a selective androgen receptor agonist) in Phase II trials. The company's portfolio also extends to prostate cancer: Sabizabulin is in Phase II trials for metastatic castration and androgen receptor targeting agent-resistant prostate cancer. VERU-100, a GnRH antagonist peptide delivered via injection, is also in Phase II for advanced hormone-sensitive prostate cancer. Beyond oncology, Veru is investigating other conditions: Zuclomiphene Citrate is in Phase II for managing hot flashes. Sabizabulin has reached Phase III for treating SARS-CoV-2 in high-risk patients susceptible to acute respiratory distress syndrome. Additionally, the firm is developing a novel pharmaceutical formulation aimed at alleviating lower urinary tract symptoms associated with an enlarged prostate in men. Originally established as The Female Health Company in 1971, the corporation adopted the name Veru Inc. in July 2017. Its corporate headquarters are situated in Miami, Florida.

Miami, FL

20 employees

www.verupharma.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Mitchell S. Steiner

View full financials

Dividends per Share

VERU Annual Dividends per Share (Dividend History)

VERU Dividend Yield

VERU Dividend Yield Chart

Annual Dividend History List

Related Charts

Dividends per Share

VERU Annual Dividends per Share (Dividend History)

VERU Dividend Yield

VERU Dividend Yield Chart

Annual Dividend History List

Related Charts